|Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes).
|Human proteasome subunits from 2-dimensional gels identified by partial sequencing.
|A role for the proteasome regulator PA28alpha in antigen presentation.
|A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome.
|Gene expression induced by BO-653, probucol and BHQ in human endothelial cells.
|Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome.
|Mapping and structural dissection of human 20 s proteasome using proteomic approaches.
|Analysis of gene expression during maturation of immature dendritic cells derived from peripheral blood monocytes.
|Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits.
|Human Aurora-B binds to a proteasome alpha-subunit HC8 and undergoes degradation in a proteasome-dependent manner.
|Complete sequencing and characterization of 21,243 full-length human cDNAs.
|20S proteasome prevents aggregation of heat-denatured proteins without PA700 regulatory subcomplex like a molecular chaperone.
|The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
|Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.
|Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells.
|HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome.
|Chemical structure-dependent gene expression of proteasome subunits via regulation of the antioxidant response element.
|MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.
|A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
|Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
|Mass spectrometric characterization of the affinity-purified human 26S proteasome complex.
|Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line.
|Low expression of cell-surface thromboxane A2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes.
|Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.
|A quantitative atlas of mitotic phosphorylation.
|Ubiquitin-independent degradation of hepatitis C virus F protein.
|Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment.
|Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
|Lysine acetylation targets protein complexes and co-regulates major cellular functions.
|Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
|Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
|Initial characterization of the human central proteome.
|System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
|Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.
|N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
|Toward a comprehensive characterization of a human cancer cell phosphoproteome.
|An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
|Crystal structure of the human 20S proteasome in complex with carfilzomib.
|Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core.
|Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
|Disassembly of the self-assembled, double-ring structure of proteasome alpha7 homo-tetradecamer by alpha6.
|Human 20S proteasome activity towards fluorogenic peptides of various chain lengths.
|Structure of the human 26S proteasome at a resolution of 3.9 Aa.
|An atomic structure of the human 26S proteasome.
|The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.